Free Trial

Lumos Pharma Q1 2024 Earnings Report

Lumos Pharma EPS Results

Actual EPS
-$1.29
Consensus EPS
-$1.21
Beat/Miss
Missed by -$0.08
One Year Ago EPS
-$0.89

Lumos Pharma Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.51 million
Beat/Miss
Missed by -$340.00 thousand
YoY Revenue Growth
N/A

Lumos Pharma Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Remove Ads

Lumos Pharma Earnings Headlines

Lumos Pharma Completes Merger and Delisting Process
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Lumos Pharma reports sustained growth in PGHD trials
See More Lumos Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lumos Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lumos Pharma and other key companies, straight to your email.

About Lumos Pharma

Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

View Lumos Pharma Profile

More Earnings Resources from MarketBeat